Our General Investigative plan places emphasis on assembling a metered dose inhaler, with components manufactured by companies including, 3M, Presspart
and Aptar Corporation, leaders in medical pharmaceutical grade, ingredients canisters, valves and actuaters (metered dose inhaler components). These components require a specific, viscosity medicine (CBD, botanical's from the marijuana plant) as manufactured by our laboratories, Super-critical CO2 extracting processes, where users activating the device receive a measured dose of medication inhaled by the patient.
Our research partners, physicians at National Jewish Health, the number one respiratory hospital in the United States, botanical genetic research experts, leaders in cannabis cultivation, Supercritical CO2 extraction and business management professionals, are devoted to the clinical testing, studies and trials to deliver the first of its kind, FDA
approved asthmatic, phytocannabinoid based, metered dose inhaler.
We are on a mission and share one vision; to overcome bronchial hyper reactivity (BHR) and improve lung function in asthmatic patients worldwide. We can achieve this goal without the concerns and known side effects of pharmaceutical rescue inhalers that exist today, including but not limited to the products; fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide and fluticasone rescue inhalers.